[1] Chinese Society of Hematology, Erythrocyte Disease (Anemia) Group of Chinese Medical Association. Diagnosis and Treatment of Neutropenia: Chinese Expert Consensus[J]. National Medical Journal of China(中华医学杂志), 2022, 102(40): 3167-3173. [2] VILLARREAL M.Neutropenia: a Brief Review[J]. Pediatr Ann. 2023 , 52(6): e238-e241. [3] ZENG SQ, ZHAI LN, CHEN WH.Zoledronic Acid Injection Possibly Inducing Rhabdomyolysis: a Case Report[J]. Chinese Journal of Osteoporosis and Bone Mineral Research(中华骨质疏松和骨矿盐疾病杂志), 2024, 17(3): 252-258. [4] SUN J, YANG MX, ZHANG ZH.Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis: a Meta-Analysis[J]. Chinese Journal of Osteoporosis(中国骨质疏松杂志), 2021, 27(9): 1333-1338, 1365. [5] LIU P, YOU HL, FENG GF, et al.Zoledronic Acid Injection Inducing Grade Ⅳ Agranulocytosis: a Case Report[J]. Herald of Medicine(医药导报), 2021, 40(7): 954-956. [6] CHEN YX, ZHANG J, YAN Y, et al.Zoledronic Acid Injection Inducing Leukopenia: a Case Report[J]. Chinese Journal of Pharma-coepidemiology(药物流行病学杂志), 2021, 30(3): 215-216. [7] SHEN WJ, CAO B, CAO GW.Zoledronic Acid Injection Inducing Pancytopenia: a Case Report[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2014, 34(19): 1700-1701. [8] KARAHASANOVIC A, THORSTEINSSON AL, BJARNASON NH, et al.Long-Term Leukopenia in a Lung Transplanted Patient with Cystic Fibrosis Treated with Zoledronic Acid: a Case Report[J]. Osteoporos Int, 2016 , 27(8): 2621-2625. [9] HARTWIG SC, SIEGEL J, SCHNEIDER PJ.Preventability and Severity Assessment in Reporting Adverse Drug Reactions[J]. Am J Hosp Pharm, 1992, 49(9): 2229-2232. [10] MANJHI PK, SINGH MP, KUMAR M. Causality, Severity, Preven-tability and Predictability Assessments Scales for Adverse Drug Reactions: a Review[J]. Cureus, 2024, 16(5): e59975. [11] ZHUANG HF, LI YZ, WANG PW, et al.Zoledronic Acid Injection in the Treatment of Postmenopausal Primary Osteoporosis: Acute Phase Adverse Drug Reactions[J]. The Chinese Journal of Clinical Pharma-cology(中国临床药理学杂志), 2019, 35(11): 1119-1121, 1131. [12] GEHRKE B, ALVES COELHO MC, BRASIL D’ALVA C, et al. Long-Term Consequences of Osteoporosis Therapy with Bisphos-phonates[J]. Arch Endocrinol Metab, 2023, 68: e220334. [13] ANDRÈS E, MALOISEL F. Idiosyncratic Drug-Induced Agranu-locytosis or Acute Neutropenia[J]. Curr Opin Hematol, 2008, 15(1): 15-21. [14] HUANG X, XIE X, HUANG S, et al.Predicting Non-Chemotherapy Drug-Induced Agranulocytosis Toxicity through Ensemble Machine Learning Approaches[J]. Front Pharmacol, 2024, 15: 1431941. [15] MUNIR F, JAVAID HW, RANA MBM, et al. Ceftriaxone-Induced Reversible Agranulocytosis: a Case Report and Review of Drug-Induced Agranulocytosis[J]. Cureus.2022, 16, 14(3): e23226. [16] RATTAY B, BENNDORF RA.Drug-Induced Idiosyncratic Agranulocytosis-Infrequent but Dangerous[J]. Front Pharmacol, 2021, 12: 727717. [17] STAMER UM, GUNDERT-REMY U, BIERMANN E, et al.Metamizol: Überlegungen Zum Monitoring Zur Frühzeitigen Diagnose Einer Agranulozytose[Dipyrone (Metamizole) : Considerations on Monitoring for Early Detection of Agranulocytosis] [J]. Schmerz, 2017, 31(1): 5-13. |